Sahin Ayse, Dalgic Nazan, Sancar Mesut, Congur Emel Celebi, Kanik Mehmet Kemal, Ilgar Sibel Degim, Bayraktar Banu, Ozdemir Haci Mustafa
Department of Pediatric Infectious Diseases, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences Turkey, Istanbul, Turkey.
Department of Clinical Pharmacy, Marmara University Faculty of Pharmacy, Istanbul, Turkey.
Sisli Etfal Hastan Tip Bul. 2022 Mar 28;56(1):62-69. doi: 10.14744/SEMB.2021.85595. eCollection 2022.
The pandemic of coronavirus disease 2019 (COVID-19) is still effective all over the world. Compared to adults, data on pediatric patients are limited. In this study, we aimed to retrospectively examine the demographic, clinical, and laboratory characteristics of pediatric patients who were followed up with the diagnosis of COVID-19 in the first 3 months of the pandemic in our hospital.
A total of 190 patients, aged 1 month-18 years, who were followed up with a definite/probable diagnosis of COVID-19, who were treated in the Pediatric Infection Clinic, were included in the study. The demographic features, clinical characteristics, and laboratory findings of the patients were retrospectively analyzed from their electronic medical records.
Eighty (42.1%) of the patients were laboratory confirmed (Polymerase chain reaction positive in nasopharyngeal swab). Mean age was 72 (2-216 months) and 102 (53.7%) patients were female. Family contact history was present in 115 (60.5%) patients. The patients were classified as asymptomatic (5.8%), mild (73.2%), moderate (18.4%), and severe/critical (2.6%) according to the severity of the disease. The most common symptoms were cough (71.1%) and fever (51.1%). Hydroxychloroquine alone or in combination was the most commonly used agent.
In our study, in which we examined the pediatric COVID-19 patients, most of the patients had a mild clinical course, but there were applications with different clinical pictures such as acute appendicitis. Therefore, COVID-19 infection, which is still very unknown, will continue to surprise us with both changing treatment protocols and clinical presentations such as multisystem inflammatory syndrome in children.
2019年冠状病毒病（COVID-19）大流行仍在全球范围内肆虐。与成人相比，关于儿科患者的数据有限。在本研究中，我们旨在回顾性研究在我院大流行的前3个月中被诊断为COVID-19并接受随访的儿科患者的人口统计学、临床和实验室特征。
本研究纳入了190例年龄在1个月至18岁之间、在儿科感染门诊接受治疗且确诊/疑似诊断为COVID-19并接受随访的患者。从他们的电子病历中回顾性分析患者的人口统计学特征、临床特征和实验室检查结果。
80例（42.1%）患者经实验室确诊（鼻咽拭子聚合酶链反应呈阳性）。平均年龄为72（2 - 216个月），102例（53.7%）患者为女性。115例（60.5%）患者有家庭接触史。根据疾病严重程度，患者被分类为无症状（5.8%）、轻度（73.2%）、中度（18.4%）和重度/危重症（2.6%）。最常见的症状是咳嗽（71.1%）和发热（51.1%）。单独使用或联合使用羟氯喹是最常用的药物。
在我们对儿科COVID-19患者的研究中，大多数患者临床病程较轻，但也有急性阑尾炎等不同临床表现的病例。因此，仍然非常未知的COVID-19感染，将继续以不断变化的治疗方案和儿童多系统炎症综合征等临床表现让我们感到惊讶。
